Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CER Research Says Abbott's Response To Similac Test Results Irresponsible

RELATED NEWS
Trade ABT now with 

Hong Kong-based CER Research Friday said Abbott Laboratories Inc.'s (ABT: Quote) response to the report released March 22 relating to the safety of the infant formula product Similac Stage 1 was "irresponsible." The report contained results which showed that the Abbott product, purchased in Hong Kong in December, failed two tests by a significant margin.

In its response, which, according to CER Research, was issued in Chinese, Abbott criticized the report for a lack of "scientific-ness, objectivity and fairness." CER Research's rebuttal claims that the results were obtained from "named and recognized laboratories and experts", adding that it has "no independent view" on the product. Further, CER Research said its attempts to contact Abbott were rebuffed.

Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After ending the previous session modestly lower, stocks are turning in a lackluster performance in early trading on Thursday. The major averages have turned mixed on the day, with the Dow benefiting from a strong gain by shares of Visa (V). Hundreds of protesters stormed Burkina Faso's parliament on Thursday and set fire to the building, preventing the lawmakers from considering a bill to extend the president's 27-year rule. Security forces opened fire on protesters, as they looted computers and televisions in the National Assembly, news agencies reported. The angry crowd then marched towards the President's office, before they were U.S. economic activity increased by more than expected in the third quarter of 2014, according to a report released by the Commerce Department on Thursday. The Commerce Department said GDP increased by 3.5 percent in the third quarter compared to 3.0 percent growth expected by economists.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.